2023 - Research.com Medicine in France Leader Award
2022 - Research.com Medicine in France Leader Award
Pierre D. Delmas spends much of his time researching Osteoporosis, Internal medicine, Endocrinology, Bone remodeling and Bone density. His work carried out in the field of Osteoporosis brings together such families of science as Surgery and Raloxifene. His biological study spans a wide range of topics, including Alendronic acid, Bisphosphonate, Hip fracture, Urology and Placebo.
The study incorporates disciplines such as Osteocalcin, Pyridinoline, Physical therapy and Gastroenterology in addition to Internal medicine. His research in Bone remodeling intersects with topics in Deoxypyridinoline, Bone tissue, Menopause, N-terminal telopeptide and Osteopenia. His biological study spans a wide range of topics, including Type I collagen, Dual-energy X-ray absorptiometry, Radiology, Hazard ratio and Prospective cohort study.
Pierre D. Delmas focuses on Internal medicine, Osteoporosis, Endocrinology, Bone remodeling and Bone mineral. His studies in Internal medicine integrate themes in fields like Osteocalcin and Pyridinoline. The various areas that Pierre D. Delmas examines in his Osteoporosis study include Placebo, Surgery and Urology.
His Surgery study which covers Bisphosphonate that intersects with Zoledronic acid. His Bone remodeling study combines topics in areas such as Biochemical markers, Alendronic acid, Bone tissue, Pathology and N-terminal telopeptide. He has included themes like Cortical bone and Tibia in his Bone mineral study.
His primary areas of investigation include Osteoporosis, Internal medicine, Endocrinology, Bone mineral and Bone remodeling. His work deals with themes such as Placebo, Surgery and Urology, which intersect with Osteoporosis. Pierre D. Delmas works mostly in the field of Internal medicine, limiting it down to concerns involving Physical therapy and, occasionally, Longitudinal study and Risk factor.
His Endocrinology study incorporates themes from Osteocalcin, Deoxypyridinoline and Pyridinoline. The concepts of his Bone mineral study are interwoven with issues in Cortical bone, Coefficient of variation, Tibia and Lumbar vertebrae. Pierre D. Delmas works mostly in the field of Bone remodeling, limiting it down to topics relating to Bone resorption and, in certain cases, Resorption.
His primary areas of study are Osteoporosis, Internal medicine, Endocrinology, Bone remodeling and Bone mineral. His Osteoporosis research includes themes of Menopause and Surgery, Zoledronic acid. His Surgery research integrates issues from Placebo, Hip fracture, Osteonecrosis of the jaw and Urology.
The Endocrinology study combines topics in areas such as Osteocalcin and Pyridinoline. His Bone remodeling research is multidisciplinary, incorporating perspectives in Hormone replacement therapy, Pill, Bone resorption and Iliac crest. His work on Mineral density as part of general Bone mineral study is frequently connected to Maturity, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger;Dennis M. Black;Bruce H. Mitlak;Ronald K. Knickerbocker.
Vitamin D3 and calcium to prevent hip fractures in elderly women
Marie C. Chapuy;Monique E. Arlot;Francois Duboeuf;Jacqueline Brun.
The New England Journal of Medicine (1992)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black;Pierre D. Delmas;Richard Eastell;Ian R. Reid.
The New England Journal of Medicine (2007)
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
L Alexeeva;P Burkhardt;C Christiansen;C Cooper.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (1994)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings;Javier San Martin;Michael R. Mcclung;Ethel S. Siris.
The New England Journal of Medicine (2009)
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
Ego Seeman;Pierre D. Delmas.
The New England Journal of Medicine (2006)
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Pierre D. Delmas;Nina H. Bjarnason;Bruce H. Mitlak;Anne-Catherine Ravoux.
The New England Journal of Medicine (1997)
Body mass index as a predictor of fracture risk: A meta-analysis
C De Laet;JA Kanis;A Oden;H Johanson.
Osteoporosis International (2005)
Predictive Value of BMD for Hip and Other Fractures
Olof Johnell;John A Kanis;Anders Oden;Helena Johansson.
Journal of Bone and Mineral Research (2005)
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study.
D Hans;P Dargent-Molina;AM Schott;JL Sebert.
The Lancet (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: